Annual Accounts Payable
$3.35 M
-$506.60 K-13.14%
December 31, 2023
Summary
- As of February 7, 2025, SLN annual accounts payable is $3.35 million, with the most recent change of -$506.60 thousand (-13.14%) on December 31, 2023.
- During the last 3 years, SLN annual accounts payable has risen by +$235.00 thousand (+7.55%).
- SLN annual accounts payable is now -38.96% below its all-time high of $5.49 million, reached on December 31, 2021.
Performance
SLN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$19.10 M
+$135.70 K+0.72%
September 1, 2024
Summary
- As of February 7, 2025, SLN quarterly accounts payable is $19.10 million, with the most recent change of +$135.70 thousand (+0.72%) on September 1, 2024.
- Over the past year, SLN quarterly accounts payable has increased by +$15.75 million (+470.23%).
- SLN quarterly accounts payable is now at all-time high.
Performance
SLN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
SLN Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.1% | +470.2% |
| 3 y3 years | +7.5% | +395.3% |
| 5 y5 years | +130.1% | +395.3% |
SLN Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -39.0% | at low | at high | +470.2% |
| 5 y | 5-year | -39.0% | +42.7% | at high | +713.7% |
| alltime | all time | -39.0% | +2502.3% | at high | >+9999.0% |
Silence Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $19.10 M(+0.7%) |
| Jun 2024 | - | $18.96 M(+43.2%) |
| Mar 2024 | - | $13.24 M(+295.3%) |
| Dec 2023 | $3.35 M(-13.1%) | $3.35 M(-77.0%) |
| Sep 2023 | - | $14.57 M(-5.3%) |
| Jun 2023 | - | $15.38 M(-6.2%) |
| Mar 2023 | - | $16.41 M(+325.5%) |
| Dec 2022 | $3.86 M(-29.7%) | $3.86 M(-76.7%) |
| Sep 2022 | - | $16.54 M(+16.5%) |
| Jun 2022 | - | $14.19 M(+40.6%) |
| Mar 2022 | - | $10.09 M(+84.0%) |
| Dec 2021 | $5.49 M(+76.2%) | $5.49 M(-55.8%) |
| Sep 2021 | - | $12.40 M(+13.9%) |
| Jun 2021 | - | $10.89 M(+249.7%) |
| Dec 2020 | $3.11 M(+32.7%) | $3.11 M(-46.3%) |
| Jun 2020 | - | $5.80 M(+147.1%) |
| Dec 2019 | $2.35 M(+61.3%) | - |
| Dec 2019 | - | $2.35 M(-35.2%) |
| Jun 2019 | - | $3.62 M(+148.9%) |
| Dec 2018 | $1.46 M(+133.1%) | - |
| Dec 2018 | - | $1.46 M(-69.1%) |
| Jun 2018 | - | $4.71 M(+654.5%) |
| Dec 2017 | $624.30 K(-3.8%) | - |
| Dec 2017 | - | $624.30 K(-82.7%) |
| Jun 2017 | - | $3.60 M(+455.1%) |
| Dec 2016 | $648.70 K(+111.5%) | - |
| Dec 2016 | - | $648.70 K(-68.3%) |
| Jun 2016 | - | $2.05 M(+567.2%) |
| Dec 2015 | $306.70 K(-63.5%) | - |
| Dec 2015 | - | $306.70 K(-78.9%) |
| Jun 2015 | - | $1.46 M(+73.2%) |
| Dec 2014 | $840.50 K(+7.1%) | - |
| Dec 2014 | - | $840.50 K(-67.7%) |
| Jun 2014 | - | $2.60 M(+231.3%) |
| Dec 2013 | $784.90 K | - |
| Dec 2013 | - | $784.90 K(-44.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $1.42 M(+736.8%) |
| Dec 2012 | $169.70 K(-75.5%) | - |
| Dec 2012 | - | $169.70 K(-88.9%) |
| Jun 2012 | - | $1.52 M(+119.5%) |
| Dec 2011 | $693.40 K(+30.2%) | - |
| Dec 2011 | - | $693.40 K(-79.2%) |
| Jun 2011 | - | $3.33 M(+525.7%) |
| Dec 2010 | $532.50 K(-47.4%) | - |
| Dec 2010 | - | $532.50 K(-87.0%) |
| Jun 2010 | - | $4.11 M(+305.9%) |
| Dec 2009 | $1.01 M(+59.6%) | - |
| Dec 2009 | - | $1.01 M(-25.7%) |
| Jun 2009 | - | $1.36 M(+114.9%) |
| Dec 2008 | $634.20 K(-48.1%) | - |
| Dec 2008 | - | $634.20 K(-59.5%) |
| Jun 2008 | - | $1.57 M(+28.2%) |
| Dec 2007 | $1.22 M(+76.2%) | - |
| Dec 2007 | - | $1.22 M(-68.5%) |
| Jun 2007 | - | $3.87 M(+458.7%) |
| Dec 2006 | $693.30 K(-0.5%) | - |
| Dec 2006 | - | $693.30 K(-43.4%) |
| Jun 2006 | - | $1.23 M(+75.9%) |
| Dec 2005 | $696.50 K(+134.1%) | - |
| Dec 2005 | - | $696.50 K(-24.6%) |
| Jun 2005 | - | $923.70 K(+210.5%) |
| Dec 2004 | $297.50 K(-47.5%) | - |
| Dec 2004 | - | $297.50 K(-47.5%) |
| Dec 2003 | $566.90 K(+62.1%) | - |
| Dec 2003 | - | $566.90 K |
| Dec 2002 | $349.80 K(+55.8%) | - |
| Dec 2001 | $224.50 K(-35.9%) | - |
| Dec 2000 | $350.40 K(-55.1%) | - |
| Dec 1999 | $780.50 K(+159.3%) | - |
| Dec 1998 | $301.00 K(-9.6%) | - |
| Dec 1997 | $332.90 K(+84.8%) | - |
| Dec 1996 | $180.10 K(+39.9%) | - |
| Dec 1995 | $128.70 K | - |
FAQ
- What is Silence Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Silence Therapeutics?
- What is Silence Therapeutics annual accounts payable year-on-year change?
- What is Silence Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Silence Therapeutics?
- What is Silence Therapeutics quarterly accounts payable year-on-year change?
What is Silence Therapeutics annual accounts payable?
The current annual accounts payable of SLN is $3.35 M
What is the all time high annual accounts payable for Silence Therapeutics?
Silence Therapeutics all-time high annual accounts payable is $5.49 M
What is Silence Therapeutics annual accounts payable year-on-year change?
Over the past year, SLN annual accounts payable has changed by -$506.60 K (-13.14%)
What is Silence Therapeutics quarterly accounts payable?
The current quarterly accounts payable of SLN is $19.10 M
What is the all time high quarterly accounts payable for Silence Therapeutics?
Silence Therapeutics all-time high quarterly accounts payable is $19.10 M
What is Silence Therapeutics quarterly accounts payable year-on-year change?
Over the past year, SLN quarterly accounts payable has changed by +$15.75 M (+470.23%)